Straits Times Index
3,325.34 -0.94 (-0.03%) Nikkei
39,654.06 +480.91 (+1.23%) Hang Seng
18,069.75 -3.15 (-0.02%) FTSE 100
8,247.79 -33.76 (-0.41%) Bitcoin USD
61,720.62 +382.14 (+0.62%) CMC Crypto 200
1,280.98 +31.86 (+2.55%)
NVO Jun 2024 130.000 put
| Previous close | 0.0400 |
| Open | 0.0300 |
| Bid | 0.0100 |
| Ask | 0.0700 |
| Strike | 130.00 |
| Expiry date | 2024-06-28 |
| Day's range | 0.0300 - 0.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | 106 |
- Yahoo Finance Video
Novo Nordisk soars, Biden vs. Trump, French Markets: Market Domination
Shares of Nvidia (NVDA) are rebounding in Tuesday's session after a three-day sell-off, while shares of Novo Nordisk (NVO) are soaring to an all-time high after its popular GLP-1 weight-loss drug Wegovy was approved in China. Meanwhile, shares of SolarEdge Technologies (SEDG) are falling after one of its customers, PM&M Electric, filed for bankruptcy. The company has announced that it expects negative free cash flow of $150 million. SolarEdge is also planning a $300 million convertible note offering, diluting value for existing shareholders. President Joe Biden and former President Donald Trump will face off in the first presidential debate on Thursday, June 27. Both are expected to present their plans for office. Yahoo Finance Senior Columnist Rick Newman joined the show to explain how US presidents exercise less control over the economy than most people realize. China Beige Book International Managing Director Shehzad Qazi joined the show to discuss the two leaders' policy positions on China and what to expect from US-China relations in the next year. French President Emmanuel Macron called a snap election after dissolving the country's parliament. According to Interior Minister Gérald Darmanin, the vote could cause civil unrest in the country. Fed Watch Advisors Founder and chief investment officer Ben Emons joined the show to give insight into the European markets ahead of the French election. For more expert insight and the latest market action, click here
- Yahoo Finance Video
Novo Nordisk stock rises on Wegovy approval in China
Shares of Novo Nordisk (NVO) are soaring to an all-time high after its popular GLP-1 weight-loss drug, Wegovy, was approved in China. Yahoo Finance's Anjalee Khemlani reports more on the story and the weight-loss drug market in China. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
BenzingaNovo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows
In a new study published in the JAMA Network Open medical journal, Novo Nordisk A/S’s (NYSE:NVO) Saxenda (liraglutide), an earlier-generation weight loss drug, reveals significant declines in bone density among patients in the hips, spine, and forearm. The study, led by Signe Sørenson Torekov of Copenhagen University, suggests that while these medications effectively reduce weight, they may compromise bone health due to caloric restriction and hormonal changes. 195 participants were randomized,
